Endometrial immune disorders create an inhospitable endometrial environment for embryonic nidation in endometriosis. CD8 + tissue resident memory T cells (CD8 +TRM) are abundant tissue resident immune cells in endometrium, …
Endometriosis is a common gynecological condition. However, endometriosis-associated malignancies occur in up to 1% of women with endometriosis. Most cases of endometriosis-associated malignancy occur in the ovary, whereas 20% of …
Gynecologic disorders, such as cervical and ovarian tumors, uterine fibroids, and endometriosis, present significant clinical challenges due to frequent recurrence, emerging chemoresistance, and undesirable effects associated with prolonged hormonal treatments. …
Endometriosis is a chronic gynecological disorder characterized by progressive fibrosis, which is closely associated with clinical symptoms such as dysmenorrhea and infertility. While myofibroblast activation is central to fibrogenesis, the …
Endometriosis is a pathological condition characterized by the ectopic growth of endometrial cells, leading to chronic pelvic pain and infertility. Epidemiological studies have associated exposure to dioxin-like polychlorinated biphenyls (PCBs), …
This study aims to identify molecular markers with prognostic value for biochemical pregnancy in follicular fluid (FF) samples from women with endometriosis after assisted reproductive technology (ART) intervention. Levels of …
How do cumulative live birth rates (CLBRs) in women with endometriosis compare to those with other infertility diagnoses undergoing ART?
The endometrium is a highly dynamic tissue central to female reproductive function, undergoing nearly 500 cycles of proliferation, differentiation, shedding, and regeneration throughout a woman's reproductive life. This remarkable regenerative …
Many experimental and clinical studies published so far demonstrate that melatonin-produced mainly by the pineal gland located deep in the middle of the brain, between the two cerebral hemispheres, and …
The ascent of novel alternative methods (NAMs) in drug development spotlights the dual needs for improved biological fidelity to in vivo along with reproducibility, especially in regulatory applications. The need …